X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA AJANTA PHARMA ALEMBIC PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 16.5 20.9 79.2% View Chart
P/BV x 3.6 3.6 100.2% View Chart
Dividend Yield % 1.1 1.0 107.9%  

Financials

 ALEMBIC PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
AJANTA PHARMA
Mar-19
ALEMBIC PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs6641,422 46.7%   
Low Rs412898 45.9%   
Sales per share (Unadj.) Rs208.7233.5 89.4%  
Earnings per share (Unadj.) Rs31.044.0 70.5%  
Cash flow per share (Unadj.) Rs37.152.2 71.2%  
Dividends per share (Unadj.) Rs5.509.00 61.1%  
Dividend yield (eoy) %1.00.8 131.7%  
Book value per share (Unadj.) Rs144.2255.1 56.5%  
Shares outstanding (eoy) m188.5288.02 214.2%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x2.65.0 51.9%   
Avg P/E ratio x17.426.4 65.8%  
P/CF ratio (eoy) x14.522.2 65.2%  
Price / Book Value ratio x3.74.5 82.1%  
Dividend payout %17.720.5 86.7%   
Avg Mkt Cap Rs m101,461102,081 99.4%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m7,4674,307 173.4%   
Avg. sales/employee Rs ThNM3,022.6-  
Avg. wages/employee Rs ThNM633.4-  
Avg. net profit/employee Rs ThNM569.1-  
INCOME DATA
Net Sales Rs m39,34720,554 191.4%  
Other income Rs m94211 44.5%   
Total revenues Rs m39,44120,765 189.9%   
Gross profit Rs m8,7365,664 154.2%  
Depreciation Rs m1,152721 159.9%   
Interest Rs m18412 1,587.1%   
Profit before tax Rs m7,4935,143 145.7%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5681,273 123.1%   
Profit after tax Rs m5,8443,870 151.0%  
Gross profit margin %22.227.6 80.6%  
Effective tax rate %20.924.8 84.5%   
Net profit margin %14.918.8 78.9%  
BALANCE SHEET DATA
Current assets Rs m19,57711,812 165.7%   
Current liabilities Rs m14,8963,776 394.5%   
Net working cap to sales %11.939.1 30.4%  
Current ratio x1.33.1 42.0%  
Inventory Days Days9077 116.0%  
Debtors Days Days4582 55.6%  
Net fixed assets Rs m27,09714,398 188.2%   
Share capital Rs m377175 214.9%   
"Free" reserves Rs m26,81122,277 120.4%   
Net worth Rs m27,18822,452 121.1%   
Long term debt Rs m4,9937 75,651.5%   
Total assets Rs m47,77826,962 177.2%  
Interest coverage x41.7444.3 9.4%   
Debt to equity ratio x0.20 62,473.3%  
Sales to assets ratio x0.80.8 108.0%   
Return on assets %12.614.4 87.6%  
Return on equity %21.517.2 124.7%  
Return on capital %23.623.0 102.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,45310,682 182.1%   
Fx outflow Rs m6,0652,102 288.5%   
Net fx Rs m13,3888,580 156.0%   
CASH FLOW
From Operations Rs m8,1203,748 216.6%  
From Investments Rs m-7,556-2,228 339.1%  
From Financial Activity Rs m590-1,475 -40.0%  
Net Cashflow Rs m1,15345 2,551.5%  

Share Holding

Indian Promoters % 74.1 73.8 100.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 1.6 187.1%  
FIIs % 9.1 7.6 119.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 17.0 81.8%  
Shareholders   49,328 20,968 235.3%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   JUBILANT LIFE SCIENCES  PLETHICO PHARMA  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Lower; Metal & Automobile Stocks Slip(12:30 pm)

Share markets in India are presently trading on a negative note. Barring finance sector, all sectoral indices are trading in red with stocks in the metal sector.

Related Views on News

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jul 18, 2019 01:01 PM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - SANOFI INDIA COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS